Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer.

Breast Cancer Res Treat · 2021 · PMC7921067 · PMID 33113088

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Conclusions In conclusion, although we observed a slight improvement in both OS and RFS in women who received concurrent trastuzumab compared to those treated sequentially, results did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.